bullish - Turbo Option Trading

Nutrien Beats Q1 Earnings and Revenue Estimates

May 9, 2024 author

Nutrien (NYSE: NTR) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.78%. A quarter ago, it was expected that […]

Earnings Beat

Kronos Worldwide Q1 Earnings and Revenues Beat Estimates

May 9, 2024 author

Kronos Worldwide (NYSE: KRO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 75%. A quarter ago, it was expected […]

Earnings Beat

Vital Farms Surpasses Q1 Earnings and Revenue Estimates

May 9, 2024 author

Vital Farms (NASDAQ: VITL) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 86.96%. A quarter ago, it was expected that […]

Earnings Beat

Royalty Pharma Beats Q1 Earnings and Revenue Estimates

May 9, 2024 author

Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected […]

Upgrades

Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

May 9, 2024 author

Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity. As of April 16, 2024, data cutoff, the Phase 1 study enrolled 35 heavily pretreated patients with advanced metastatic solid tumor types. CX-904 demonstrated a favorable safety profile, supporting administration and […]

Upgrades

SiTime Stock Skyrockets 30% After Analyst Upgrade

May 9, 2024 author

SiTime Corp (NASDAQ:SITM) shares are trading higher after Needham analyst Quinn Bolton upgraded the stock rating from Hold to Buy with a $130 price target. SiTime posted revenue of $33.0 million, down 13.9% year over year, but above Bolton’s estimate and the Street’s $32 million estimate, due to downward trends in customer inventories that resulted in a pickup in order activity. Only […]

Upgrades

EVgo’s Q1 Performance Sparks Optimism, Analyst Upgrades Stock

May 9, 2024 author

Cantor Fitzgerald analyst Andres Sheppard upgraded the shares of EVgo Inc (NASDAQ:EVGO) from Neutral to Overweight and lowered the price target from $5 to $4. EVGO reported a first-quarter FY24 sales jump of 118.2% year-on-year to $55.16 million, beating the analyst consensus estimate of $52.389 million. EPS of $(0.09) beat the analyst consensus estimate of $(0.14). EVgo also announced that Olga […]

Upgrades

Affirm Holdings Selloff Is ‘Baffling’: Analysts Dive Into Financial Results

May 9, 2024 author

Shares of Affirm Holdings Inc (NASDAQ:AFRM) were climbing in early trading on Thursday, after dropping more than 9% on Wednesday, after the company reported its fiscal third-quarter results. The results came amid an exciting earnings season. Here are some key analyst takeaways. JPMorgan On Affirm Holdings Analyst Reginald Smith upgraded the rating from Neutral to […]

Earnings Beat

Perrigo Q1 Earnings Surpass, Sales Miss Estimates

May 9, 2024 author

Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimate of 24 cents. Earnings were down 35.6% year over year, primarily due to a negative financial impact of 30 cents per share from infant formula. Net sales declined 8.4% year over […]

Earnings Beat

EverQuote Q1 Earnings Top Estimates, Revenues Fall Y/Y

May 9, 2024 author

EverQuote (NASDAQ: EVER) delivered first-quarter 2024 earnings per share of 5 cents in contrast to the Zacks Consensus Estimate of a loss of 7 cents as well as the year-ago quarter’s loss of 8 cents per share. Though the top line of $91 million declined 16.5% year over year, it beat the Zacks Consensus Estimate […]

Share this video